Wedbush Reaffirms “Outperform” Rating for Perspective Therapeutics (NASDAQ:CATX)

Perspective Therapeutics (NASDAQ:CATX)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a research note issued to investors on Friday,Benzinga reports. They presently have a $11.00 target price on the stock. Wedbush’s price target suggests a potential upside of 190.24% from the company’s current price.

Other analysts also recently issued reports about the company. B. Riley cut their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. BTIG Research reissued a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 13th. HC Wainwright lifted their price objective on Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday. UBS Group reduced their price objective on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, November 21st. Finally, Truist Financial began coverage on Perspective Therapeutics in a research report on Monday, November 24th. They set a “buy” rating and a $12.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $11.17.

Perspective Therapeutics Stock Down 11.0%

NASDAQ:CATX opened at $3.79 on Friday. The firm has a market cap of $281.74 million, a price-to-earnings ratio of -4.21 and a beta of 1.18. The company has a 50-day moving average price of $2.63. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $6.16.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently modified their holdings of the business. R Squared Ltd acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $44,000. UBS Group AG increased its holdings in Perspective Therapeutics by 44.5% during the 4th quarter. UBS Group AG now owns 926,331 shares of the company’s stock valued at $2,547,000 after acquiring an additional 285,188 shares in the last quarter. Trueblood Wealth Management LLC increased its stake in shares of Perspective Therapeutics by 72.4% during the 4th quarter. Trueblood Wealth Management LLC now owns 119,061 shares of the company’s stock worth $327,000 after purchasing an additional 50,000 shares in the last quarter. Taylor & Morgan Wealth Management LLC raised its holdings in shares of Perspective Therapeutics by 6.6% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after acquiring an additional 6,000 shares during the last quarter. Finally, Auctus Advisors LLC purchased a new stake in Perspective Therapeutics during the 4th quarter worth about $87,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.